Paradoxical LDL-C Increase after Switching from PCSK9 Inhibitors to Inclisiran: A Real-World Case Series. [PDF]
Acta Cardiol SinChua SK, Hung HF, Jong BH, Chen LC.
europepmc +1 more source
Compound heterozygous low-density lipoprotein receptor variants causing homozygous of familial hypercholesterolemia in two sisters: a case report. [PDF]
Transl PediatrLi C +5 more
europepmc +1 more source
Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells. [PDF]
BMC Cardiovasc DisordZulkapli R +4 more
europepmc +1 more source
Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin. [PDF]
Front PharmacolLi F, Ye H, Chen L, Ma Y, Chen S.
europepmc +1 more source
Prescribing Patterns of Evolocumab and Alirocumab in Patients With Familial Hypercholesterolemia: A Cross-Sectional Study Using the National Ambulatory Medical Care Survey, 2018-2019. [PDF]
CureusOkorigba EM +5 more
europepmc +1 more source
The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease. [PDF]
Am J Prev CardiolRazavi AC, Shapiro MD.
europepmc +1 more source
Antibody-Based Therapeutics for Hypercholesterolemia. [PDF]
BiologicsTomlinson B, Chan P.
europepmc +1 more source
Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study. [PDF]
Healthcare (Basel)AlRuthia Y +7 more
europepmc +1 more source
Dosis máximas de estatinas pueden evitar el uso de los inhibidores de la PCSK9 [PDF]
, 2019 Abad Santos, Francisco
core
Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. [PDF]
J Atheroscler ThrombShimizu Y +11 more
europepmc +1 more source